智通财经APP获悉，先声药业(02096)涨超9%，截至发稿，涨9.17%，报11.9港元，成交额3.6亿港元。
消息面上，今年以来，先声药业迎来创新管线的多重突破，包括新一代抗失眠药科唯可（盐酸达利雷生片）获国家药监局批准上市、年内分别就两项产品SIM0500、SIM0505 与艾伯维、NextCure 达成战略合作等。瑞银认为，市场尚未充分反映先声药业的研发实力及创新药销售潜力。其创新成果正加速兑现——2024年获批两款新药，今年迄今再添两款，2026至2027年可能还有4款获批。该行指，公司今年关键催化剂包括：1) SIM0500及其他早期候选药物的数据读取；2)ADC或T细胞衔接器(TCE)技术平台可能达成的额外授权协议。广发证券表示，公司创新转型成功，自研与合作新药进展顺利。维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.